KAI1/CD82 is a member of the tetraspanin superfamily and has been re-discovered as a cancer metastasis suppressor. But the mechanism of the KAI1/CD82-mediated suppression of cancer metastasis still remains unclear. Similar to other tetraspanins, KAI1/CD82 has been reported to regulate cell migration and cancer cell invasiveness. Our studies indicate that: 1) restoration of the KAI1/CD82 expression in prostate cancer cells inhibits cell motility, 2) the FAK-p130CAS/CrK-paxillin signaling pathway is required for KAI1/CD82-mediated suppression of prostate cancer cell motility, 3) KAI1/CD82 disrupts the formation of motility-related subcellular structures such as focal adhesion and cortical actin network, 4) KASP (or EWI2/PGRL), a novel Ig superfamily protein, was identified as a KAI1/CD82-binding protein, and 5) KASP (or EWI2/PGRL) functionally coordinates with KAI 1/CD82 in cell migration. Therefore, we hypothesize that the KAI1/CD82-mediated suppression of cancer metastasis depends on its inhibition of cell motility through 1) regulating the intracellular signaling pathways that control cell movement, and 2) participating the transmembrane complex that is involved in cell movement. So, we propose to first define the structural and functional elements in KAI1/CD82 molecule responsible for the inhibition of cell motility and invasiveness. In particular, the roles of specific biochemical features such as acylation, internalization, and KASP (or EWl2/PGRL) association in cancer cell motility and invasiveness will be determined, in order to conclusively link a specific biochemical feature of KAI1/CD82 to its inhibition of cell motility. Second, we will assess the role of KASP (or EWI2/PGRL) in KAI1/CD82-mediated suppression of cancer cell motility and invasiveness. Third, we will assess how the biochemical feature(s) required for the motility-inhibition affects cell motility by analyzing cell motility-related cellular functions such as adhesion, spreading, and vesicle trafficking and cell motility-related molecular signaling. Together, these studies will identify the mechanism responsible for the KAI1/CD82-mediated suppression of cancer metastasis. Understanding the mechanistic roles of KAI1/CD82 in cancer cell motility will promises to lead to the development of therapeutics capable of specially inhibiting cancer metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA096991-03
Application #
7025000
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Woodhouse, Elizabeth
Project Start
2004-03-01
Project End
2009-02-28
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
3
Fiscal Year
2006
Total Cost
$224,547
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Huang, Chao; Dai, Jingxing; Zhang, Xin A (2015) Environmental physical cues determine the lineage specification of mesenchymal stem cells. Biochim Biophys Acta 1850:1261-6
Li, Xin; Zhang, Xin A; Xie, Wei et al. (2015) MYC-mediated synthetic lethality for treatment of hematological malignancies. Curr Cancer Drug Targets 15:53-70
Li, Xin; Zhang, Xin A; Li, Xiaoqing et al. (2015) MYC-mediated synthetic lethality for treating tumors. Curr Cancer Drug Targets 15:99-115
Feng, Jin; Huang, Chao; Wren, Jonathan D et al. (2015) Tetraspanin CD82: a suppressor of solid tumors and a modulator of membrane heterogeneity. Cancer Metastasis Rev 34:619-33
Wei, Quan; Zhang, Feng; Richardson, Mekel M et al. (2014) CD82 restrains pathological angiogenesis by altering lipid raft clustering and CD44 trafficking in endothelial cells. Circulation 130:1493-504
Peng, Dan; Zuo, Houjuan; Liu, Zhengxiang et al. (2013) The tetraspanin CD151-ARSA mutant inhibits angiogenesis via the YRSL sequence. Mol Med Rep 7:836-42
Scheffer, Konstanze D; Gawlitza, Alexander; Spoden, Gilles A et al. (2013) Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J Virol 87:3435-46
Liu, Wei M; Zhang, Feng; Moshiach, Simon et al. (2012) Tetraspanin CD82 inhibits protrusion and retraction in cell movement by attenuating the plasma membrane-dependent actin organization. PLoS One 7:e51797
Guo, Qiusha; Xia, Bing; Zhang, Feng et al. (2012) Tetraspanin CO-029 inhibits colorectal cancer cell movement by deregulating cell-matrix and cell-cell adhesions. PLoS One 7:e38464
Zhang, Xin A; Huang, Chao (2012) Tetraspanins and cell membrane tubular structures. Cell Mol Life Sci 69:2843-52

Showing the most recent 10 out of 23 publications